Do you want to read an article? Please log in or register.
Efficacy and Safety of Budesonide Orodispersible Tablets for Eosinophilic Esophagitis up to 3 Years: an Open-Label Extension Study
Esophagus Diseases
COMMENTED
Related content
Esophagus Diseases
Long-Term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: a 4-Year, Phase 3, Open-Label Study
Clin Gastroenterol Hepatol
Dellon ES, Katzka DA, Mukkada VA, Collins MH, Falk GW, Richmond CA, Terreri B, Thakur M, Boules M, Goodwin B, Hirano I
doi: 10.1016/j.cgh.2024.12.024
Inflammatory Bowel Disease
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflamm Bowel Dis
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A
doi: 10.1093/ibd/izae253
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
Inflammatory Bowel Disease
Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies
J Crohns Colitis
Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M
doi: 10.1093/ecco-jcc/jjaf005
Inflammatory Bowel Disease
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 GRAVITI Study
Gastroenterology
Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G
doi: 10.1053/j.gastro.2025.02.033
COMMENTED
Esophagus Diseases
Cohort Profile Update: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS)
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Inflamm Intest Dis
El-Khoury JW, Safroneeva E, Saner C, Rossel JB, Trelle S, Zwahlen M, Biedermann L, Kreienbuehl A, Greuter T, Schreiner P, Netzer P, Franke A, Brand S, Hasler C, Aepli P, Burri E, Weber A, Sempoux C, Biral R, Jochum W, Diebold J, Willi N, Straumann A, Schoepfer AM, Swiss EoE Cohort Study Group
doi: 10.1159/000539713
Inflammatory Bowel Disease
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials
Clin Gastroenterol Hepatol
Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N
doi: 10.1016/j.cgh.2024.08.032
Esophagus Diseases
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
N Engl J Med
Chehade M, Dellon ES, Spergel JM, Collins MH, Rothenberg ME, Pesek RD, Hirano I, Liu R, Laws E, Mortensen E, Martincova R, Shabbir A, McCann E, Kamal MA, Kosloski MP, Hamilton JD, Samuely C, Lim WK, Wipperman MF, Farrell A, Patel N, Yancopoulos GD, Glotfelty L, Maloney J
doi: 10.1056/NEJMoa2312282